Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Monica Mann_2023
VIEWPOINTS

Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research

Shots:Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meetingThe highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiativesThe interview shows how Biogen develops, and delivers…
May 31, 2023

Read more

VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023
VIEWPOINTS

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots:Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platformMark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
May 4, 2023

Read more

VIEWPOINTS_Jason-Winnike_2023
VIEWPOINTS

Jason Winnike, Study Director at Metabolon Shares Insights from the Launch of its Oxysterol Targeted Panel

Shots:Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer The interview gives a profound understanding…
March 6, 2023

Read more

Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Molecular Farming: Paving a Modern Track for Pharmaceutical Sectors (Molecular Pharming)

Technologies and innovations have transformed the world globally. Traveling to different places, interacting with new people, working remotely from home, and much more comes with evolving technologies. With all these bright perspectives, it’s also an indisputable fact that we are now more susceptible to diseases than we were a few decades ago. After the outbreak…
February 20, 2023

Read more

VIEWPOINTS_John Gabrielson_2023
VIEWPOINTS

John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs

Shots: John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disordersUnder the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
February 2, 2023

Read more

Spotlight Interview_Bruce Bauer & Kendall Morrison
SPOTLIGHT

Spotlight Interview with Bruce Bauer (CEO) & Kendall Morrison (CSO) at TAE Life Sciences

PharmaShots conducted its fourth “Spotlight- Company of the Month with TAE Life Sciences”. In conversation with Bruce Bauer (CEO) & Kendall Morrison (CSO) at TAE Life Sciences, they both shared insights on TAE Life Sciences' vision, upcoming plans, technologies used, and developing products. Bruce and Kendall spoke about TAE’s novel treatment options which could potentially…
December 5, 2022

Read more

PharmaShots Interview Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy
VIEWPOINTS

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

Shots: Laurent spoke about the study design of its nanoparticle therapy to enhance the cancer-killing effect of radiation, which was presented at ASCO 2022Laurent also highlighted how this nanoparticle therapy can be a potential radio enhancer in various tumor types and across lines of therapyThe interview summarizes Nanobiotix’s vision to advance nanoparticles across…
August 10, 2022

Read more

PharmaShots Interview Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer
VIEWPOINTS

PharmaShots Interview: Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer

Shots: Purnanand spoke about the preclinical results of lead candidate in oncology and how its identifies IL-38 as a target to treat cancerPurnanand also talked about Immunome’s collaboration with Fox Chase Cancer Center for the further development of its prime productThe interview gives a understanding of Immunome’s goal of developing therapeutics to treat…
August 2, 2022

Read more

Exclusive_Barbara Klencke_2022
EXCLUSIVE

Barbara Klencke, CMO at Sierra Oncology (now GSK) Shares Insights on the Significant benefits obtained from the Pivotal Myelofibrosis Study

Shots:Barbara gave a comprehensive view of the P-III (MOMENTUM) clinical study results which evaluates its lead candidate in myelofibrosisSierra is now acquired by GSK (completed on 1st July 2022) resulting in GSK commercializing this prime product once approvedThe interview outlines Sierra’s (now GSK) vision to develop transformative therapies for rare cancersSmriti: Thank…
July 18, 2022

Read more

PharmaShots Interview In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility
VIEWPOINTS

PharmaShots Interview: In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility

Shots:Brian spoke about opening of its new liquid biopsy lab in Phoenix, AZ and an investment of $45M for the development of its facilitiesBrian also talked about the establishment of lab will enhance company’s molecular profiling capabilities and launch of a blood-based diagnostic assayThe interview gives a view of how Caris Life…
July 4, 2022

Read more

Load more